Funding research and development from cash generated by operating activities
First written in FY2019. 23 of 24 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reaffirmed its funding policy of allocating funds generated from operating activities to operating funding needs and R&D. Cash flow from operating activities was ¥430,680 million, and R&D expenses were ¥32,839 million. - FY2026-H1RestatedAnnual report
「The principal funding needs of the Group are funds required for operating activities and R&D funds for planning and development. These needs are funded with cash generated from operating activities. Total R&D expenses for the interim consolidated accounting period were ¥16,582 million.」
The company reaffirmed its funding policy of allocating funds generated from operating activities to operating funding needs and R&D. R&D expenses for the interim consolidated accounting period were ¥16,582 million, and cash flow from operating activities was ¥196,882 million. - FY2025-H1RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reaffirmed its funding policy of allocating funds generated from operating activities to operating funding needs and R&D. R&D expenses for the interim consolidated accounting period were ¥14,688 million, and cash flow from operating activities was ¥209,621 million. - FY2025-Q1RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reaffirmed its funding policy of allocating funds generated from operating activities to operating funding needs and R&D. R&D expenses for the cumulative first quarter of the consolidated fiscal year were ¥7,102 million. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥18,355 million. The principal funding needs of the Group are funds required for operating activities and R&D funds for planning and development. These needs are funded with cash generated from operating activities.」
The company reaffirmed its funding policy of allocating funds generated from operating activities to operating funding needs and R&D, and disclosed R&D expenses of ¥18,355 million for the cumulative third quarter of the consolidated fiscal year. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥11,945 million. The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reaffirmed its funding policy of allocating funds generated from operating activities to operating funding needs and R&D, and disclosed R&D expenses of ¥11,945 million for the cumulative second quarter of the consolidated fiscal year. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥5,945 million. The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥5,945 million for the first quarter of the current consolidated cumulative period. - FY2023RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses. Cash flows from operating activities were ¥302,628 million, and research and development expenses were ¥21,660 million. - FY2023-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥16,017 million. The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥16,017 million. - FY2023-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥10,514 million. The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥10,514 million. - FY2023-Q1RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥4,780 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥4,780 million for the first quarter of the current consolidated cumulative period. - FY2022RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses. Cash flows from operating activities were ¥271,476 million, and research and development expenses were ¥17,872 million. - FY2022-Q3RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥13,263 million.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥13,263 million for the third quarter of the current consolidated cumulative period. - FY2022-Q2RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥8,634 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥8,634 million for the second quarter of the current consolidated cumulative period. - FY2022-Q1RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥4,311 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥4,311 million for the first quarter of the current consolidated cumulative period. - FY2021RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses. Cash flows from operating activities were ¥192,652 million, and research and development expenses were ¥16,084 million. - FY2021-Q3RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses. - FY2021-Q2RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥7,786 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥7,786 million for the second quarter of the current consolidated cumulative period. - FY2021-Q1RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses. - FY2020RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company reconfirms its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses. Cash flows from operating activities were ¥203,434 million, and research and development expenses were ¥16,279 million. - FY2020-Q3RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥12,000 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥12,000 million for the third quarter of the current consolidated cumulative period. - FY2020-Q2RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥8,075 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses research and development expenses of ¥8,075 million for the second quarter of the current consolidated cumulative period. - FY2020-Q1RestatedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities. Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥3,940 million.」
The company reconfirms its policy of allocating cash generated from operating activities to operating needs and research and development expenses, and discloses first-quarter research and development expenses of ¥3,940 million. - FY2019First statedAnnual report
「The Group's primary funding needs are funds required for operating activities and research and development funds for planning and development, and these needs are to be funded with cash generated from operating activities.」
The company describes, for the first time as a standalone topic, its funding policy of allocating cash generated from operating activities to operating needs and research and development expenses related to planning and development.